Total Payments
$42,200
2024 Payments
$11,100
Companies
3
Transactions
24
Payment Breakdown by Category
Consulting$39,350 (93.2%)
Research$2,850 (6.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $39,350 | 22 | 93.2% |
| Unspecified | $2,850 | 2 | 6.8% |
Payments by Type
General
$39,350
22 transactions
Research
$2,850
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $22,700 | 13 | $0 (2021) |
| Sumitomo Pharma America, Inc. | $11,100 | 6 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $8,400 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,100 | 6 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($5,550) |
| 2023 | $5,550 | 3 | Sumitomo Pharma America, Inc. ($5,550) |
| 2021 | $7,800 | 5 | Sunovion Pharmaceuticals Inc. ($7,800) |
| 2020 | $6,700 | 3 | Sunovion Pharmaceuticals Inc. ($3,850) |
| 2019 | $2,550 | 2 | Sunovion Pharmaceuticals Inc. ($2,550) |
| 2018 | $3,400 | 2 | Sunovion Pharmaceuticals Inc. ($3,400) |
| 2017 | $5,100 | 3 | Sunovion Pharmaceuticals Inc. ($5,100) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/18/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 07/18/2024 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 02/15/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 02/15/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 02/15/2024 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 02/15/2024 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 06/01/2023 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 04/13/2023 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 04/13/2023 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 10/21/2021 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 05/27/2021 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 05/06/2021 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 01/28/2021 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 01/28/2021 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| 02/06/2020 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| 01/15/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | Cash or cash equivalent | $1,425.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (TRIAL 405-201-00013) | ||||||
| 01/15/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | Cash or cash equivalent | $1,425.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (TRIAL 405-201-00014) | ||||||
| 08/08/2019 | Sunovion Pharmaceuticals Inc. | DASOTRALINE (Drug) | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| Category: CNS | ||||||
| 03/14/2019 | Sunovion Pharmaceuticals Inc. | DASOTRALINE (Drug) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: CNS | ||||||
| 12/06/2018 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| 04/26/2018 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| 12/21/2017 | Sunovion Pharmaceuticals Inc. | SEP-225289 (Drug) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: CNS | ||||||
| 09/21/2017 | Sunovion Pharmaceuticals Inc. | SEP-225289 (Drug) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: CNS | ||||||
| 04/20/2017 | Sunovion Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (TRIAL 405-201-00013) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,425 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (TRIAL 405-201-00014) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,425 | 1 |
About Dr. Stephen Strakowski, MD
Dr. Stephen Strakowski, MD is a Psychiatry healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720009541.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Strakowski, MD has received a total of $42,200 in payments from pharmaceutical and medical device companies, with $11,100 received in 2024. These payments were reported across 24 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($39,350).
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Psychiatry, Psychiatry
- Location Austin, TX
- Active Since 07/21/2006
- Last Updated 05/16/2022
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1720009541
Products in Payments
- SEP-225289 (Drug) $3,400
- DASOTRALINE (Drug) $2,550
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Austin
Dr. Donald Garcia, Md, MD
Psychiatry — Payments: $4.0M
Psychiatry $4.0M
Dr. Arvinder Pal Walia, M.d, M.D
Psychiatry — Payments: $2.7M
Psychiatry $2.7M
Charles Nemeroff, Md Phd, MD PHD
Psychiatry — Payments: $400,808
Psychiatry $400,808
Dr. Divyansu Patel, M.d, M.D
Psychiatry — Payments: $319,461
Psychiatry $319,461
Frank Floca, Md, MD
Psychiatry — Payments: $99,177
Psychiatry $99,177
Dr. Charles Sweet, M.d., M.p.h, M.D., M.P.H
Psychiatry — Payments: $88,371
Psychiatry $88,371